Global Amlodipine Besylate Market 2026-2030

Description

The global amlodipine besylate market is forecasted to grow by USD 210.5 mn during 2025-2030, accelerating at a CAGR of 3.3% during the forecast period. The report on the global amlodipine besylate market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by prevalence of hypertension and chronic cardiovascular conditions, demographic shift toward aging global population, increasing adoption of fixed dose combination therapies.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Market Scope
Base Year	2025
End Year	2030
Series Year	2026-2030
Growth Momentum	Accelerate
YOY 2026	3.2%
CAGR	3.3%
Incremental Value	$210.5 mn

Technavio's global amlodipine besylate market is segmented as below:

By Application

High blood pressure
Heart diseases

By Type

Five mg tablets
Ten mg tablets
Two and half mg tablets

By End-User

Hospitals and clinics
Homecare
Public healthcare programs

Geography

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
Asia
Rest of World (ROW)
Rest of World (ROW)

This study identifies the integration of digital health and remote patient monitoring as one of the prime reasons driving the global amlodipine besylate market growth during the next few years. Also, strategic emphasis on supply chain resilience and sustainable manufacturing and regulatory frameworks and price control policies impacting market dynamics will lead to sizable demand in the market.

The report on the global amlodipine besylate market covers the following areas:

Global amlodipine besylate market sizing
Global amlodipine besylate market forecast
Global amlodipine besylate market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global amlodipine besylate market vendors that include AdvaCare Pharma, Aetos Lifecare Pvt. Ltd., Apotex Inc., Aurobindo Pharma Ltd., Cadila Pharmaceuticals Ltd., Century Pharmaceuticals Ltd., Cipla Inc., Daiichi Sankyo Co. Ltd., Dr. Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Lupin Ltd., Orbion Pharmaceuticals Pvt. Ltd., Pfizer Inc., Sandoz Group AG, Taj Pharmaceutical Ltd., Teva Pharmaceutical Ltd., Viatris Inc., Wellona Pharma, Zydus Lifesciences Ltd.. Also, the global amlodipine besylate market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR73747

1 Executive Summary

1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
2.3 Factors of disruption
2.4 Impact of drivers and challenges

3 Market Landscape

3.1 Market ecosystem
3.2 Market characteristics
3.3 Value chain analysis

4 Market Sizing

4.1 Market definition
4.2 Market segment analysis
- Market segments
4.3 Market size 2025
4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

5.1 Global Amlodipine Besylate Market 2020 - 2024
- Historic Market Size - Data Table on Global Amlodipine Besylate Market 2020 - 2024 ($ million)
5.2 Application segment analysis 2020 - 2024
- Historic Market Size - Application Segment 2020 - 2024 ($ million)
5.3 Type segment analysis 2020 - 2024
- Historic Market Size - Type Segment 2020 - 2024 ($ million)
5.4 End-user segment analysis 2020 - 2024
- Historic Market Size - End-user Segment 2020 - 2024 ($ million)
5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

6.1 Impact of AI in global amlodipine besylate market
6.2 Impact of geopolitical conflict for global amlodipine besylate market

7 Five Forces Analysis

7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
7.7 Market condition

8 Market Segmentation by Application

8.1 Market segments
8.2 Comparison by Application
8.3 High blood pressure - Market size and forecast 2025-2030
8.4 Heart diseases - Market size and forecast 2025-2030
8.5 Market opportunity by Application
- Market opportunity by Application ($ million)

9 Market Segmentation by Type

9.1 Market segments
9.2 Comparison by Type
9.3 Five mg tablets - Market size and forecast 2025-2030
9.4 Ten mg tablets - Market size and forecast 2025-2030
9.5 Two and half mg tablets - Market size and forecast 2025-2030
9.6 Market opportunity by Type
- Market opportunity by Type ($ million)

10 Market Segmentation by End-user

10.1 Market segments
10.2 Comparison by End-user
10.3 Hospitals and clinics - Market size and forecast 2025-2030
10.4 Homecare - Market size and forecast 2025-2030
10.5 Public healthcare programs - Market size and forecast 2025-2030
10.6 Market opportunity by End-user
- Market opportunity by End-user ($ million)

11 Customer Landscape

11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

12.1 Geographic segmentation
12.2 Geographic comparison
12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 India - Market size and forecast 2025-2030
- 12.5.3 Japan - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Indonesia - Market size and forecast 2025-2030
- 12.5.6 Thailand - Market size and forecast 2025-2030
12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.3 UAE - Market size and forecast 2025-2030
- 12.6.4 Turkey - Market size and forecast 2025-2030
- 12.6.5 Argentina - Market size and forecast 2025-2030
- 12.6.6 Colombia - Market size and forecast 2025-2030
- 12.6.7 South Africa - Market size and forecast 2025-2030
- 12.6.8 Israel - Market size and forecast 2025-2030
12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

13.1 Market drivers
- Prevalence of hypertension and chronic cardiovascular conditions
- Demographic shift toward aging global population
- Increasing adoption of fixed dose combination therapies
13.2 Market challenges
- Intensifying price erosion and commodity driven market competition
- Stringent regulatory compliance and quality assurance hurdles
- Disruption of global raw material volatility
13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
13.4 Market opportunities
- Integration of digital health and remote patient monitoring
- Strategic emphasis on supply chain resilience and sustainable manufacturing
- Regulatory frameworks and price control policies impacting market dynamics

14 Competitive Landscape

14.1 Overview
14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
14.3 Landscape disruption
- Overview on factors of disruption
14.4 Industry risks
- Impact of key risks on business

15 Competitive Analysis

15.1 Companies profiled
- Companies covered
15.2 Company ranking index
- Company ranking index
15.3 Market positioning of companies
- Matrix on companies position and classification
15.4 Apotex Inc.
- Apotex Inc. - Overview
- Apotex Inc. - Product / Service
- Apotex Inc. - Key offerings
- SWOT
15.5 Aurobindo Pharma Ltd.
- Aurobindo Pharma Ltd. - Overview
- Aurobindo Pharma Ltd. - Business segments
- Aurobindo Pharma Ltd. - Key news
- Aurobindo Pharma Ltd. - Key offerings
- Aurobindo Pharma Ltd. - Segment focus
- SWOT
15.6 Cadila Pharmaceuticals Ltd.
- Cadila Pharmaceuticals Ltd. - Overview
- Cadila Pharmaceuticals Ltd. - Product / Service
- Cadila Pharmaceuticals Ltd. - Key offerings
- SWOT
15.7 Cipla Inc.
- Cipla Inc. - Overview
- Cipla Inc. - Business segments
- Cipla Inc. - Key news
- Cipla Inc. - Key offerings
- Cipla Inc. - Segment focus
- SWOT
15.8 Daiichi Sankyo Co. Ltd.
- Daiichi Sankyo Co. Ltd. - Overview
- Daiichi Sankyo Co. Ltd. - Business segments
- Daiichi Sankyo Co. Ltd. - Key news
- Daiichi Sankyo Co. Ltd. - Key offerings
- Daiichi Sankyo Co. Ltd. - Segment focus
- SWOT
15.9 Dr. Reddys Laboratories Ltd.
- Dr. Reddys Laboratories Ltd. - Overview
- Dr. Reddys Laboratories Ltd. - Business segments
- Dr. Reddys Laboratories Ltd. - Key news
- Dr. Reddys Laboratories Ltd. - Key offerings
- Dr. Reddys Laboratories Ltd. - Segment focus
- SWOT
15.10 Glenmark Pharmaceuticals Ltd.
- Glenmark Pharmaceuticals Ltd. - Overview
- Glenmark Pharmaceuticals Ltd. - Product / Service
- Glenmark Pharmaceuticals Ltd. - Key news
- Glenmark Pharmaceuticals Ltd. - Key offerings
- SWOT
15.11 Intas Pharmaceuticals Ltd.
- Intas Pharmaceuticals Ltd. - Overview
- Intas Pharmaceuticals Ltd. - Product / Service
- Intas Pharmaceuticals Ltd. - Key offerings
- SWOT
15.12 Lupin Ltd.
- Lupin Ltd. - Overview
- Lupin Ltd. - Business segments
- Lupin Ltd. - Key news
- Lupin Ltd. - Key offerings
- Lupin Ltd. - Segment focus
- SWOT
15.13 Orbion Pharmaceuticals Pvt. Ltd.
- Orbion Pharmaceuticals Pvt. Ltd. - Overview
- Orbion Pharmaceuticals Pvt. Ltd. - Product / Service
- Orbion Pharmaceuticals Pvt. Ltd. - Key offerings
- SWOT
15.14 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Segment focus
- SWOT
15.15 Sandoz Group AG
- Sandoz Group AG - Overview
- Sandoz Group AG - Business segments
- Sandoz Group AG - Key news
- Sandoz Group AG - Key offerings
- Sandoz Group AG - Segment focus
- SWOT
15.16 Teva Pharmaceutical Ltd.
- Teva Pharmaceutical Ltd. - Overview
- Teva Pharmaceutical Ltd. - Business segments
- Teva Pharmaceutical Ltd. - Key news
- Teva Pharmaceutical Ltd. - Key offerings
- Teva Pharmaceutical Ltd. - Segment focus
- SWOT
15.17 Viatris Inc.
- Viatris Inc. - Overview
- Viatris Inc. - Business segments
- Viatris Inc. - Key news
- Viatris Inc. - Key offerings
- Viatris Inc. - Segment focus
- SWOT
15.18 Zydus Lifesciences Ltd.
- Zydus Lifesciences Ltd. - Overview
- Zydus Lifesciences Ltd. - Business segments
- Zydus Lifesciences Ltd. - Key news
- Zydus Lifesciences Ltd. - Key offerings
- Zydus Lifesciences Ltd. - Segment focus
- SWOT

16 Appendix

16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
16.3 Currency conversion rates for US$
- Currency conversion rates for US$
16.4 Research methodology
- Research methodology
16.5 Data procurement
- Information sources
16.6 Data validation
- Data validation
16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
16.8 Data synthesis
- Data synthesis
16.9 360 degree market analysis
- 360 degree market analysis
16.10 List of abbreviations
- List of abbreviations